Antag Therapeutics Raises €80M in Series A Financing
Summary
Antag Therapeutics, a Copenhagen, Denmark-based biopharmaceutical company developing new treatments for obesity, raised €80M in Series A funding. The company intends to use the funds to support the clinical development of AT-7687, a novel, once-weekly subcutaneous antagonist of the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) and to accelerate the expansion of its pipeline of monthly injectable therapies. Led by CEO Alexander Hovard Sparre-Ulrich, Antag Therapeutics is a clinical-stage biopharmaceutical company committed to discovering and developing new therapies for obesity and cardiometabolic diseases through GIP receptor antagonism. AT-7687 is a peptide designed to be co-administrated with current or future obesity therapies including GLP-1 medicines to deliver superior weight loss and metabolic benefits. Antag’s pipeline also includes combinations beyond GLP-1 receptor agonists and a follow-on molecule that enables monthly administration.